It is widely recognized in the medical community that the prognosis for patients with the following types of lymphoma is relatively good: lymphocyte-dominant type, stage I and II, and no systemic symptoms. According to the International Prognostic Indicators (IPI) for non-Hodgkin’s lymphoma proposed by Shipp et al. in 1993, age greater than 60 years old, stage III or IV, more than one lesion other than lymph node, bedridden or needing care from other people, and elevated serum lactate dehydrogenase are the five IPIs that have a poor prognosis. But the true determinants vary from person to person, and the confidence and determination of the lymphoma patient to overcome the disease is crucial.